Published in J Clin Invest on January 15, 1998
Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J (2001) 2.97
PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol (2002) 2.12
Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer (2003) 1.61
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest (2008) 1.43
MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci (2010) 1.25
Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol (2006) 1.24
A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J Biol Chem (2008) 1.22
Targeting the cell cycle for cancer therapy. Br J Cancer (2002) 1.12
The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol (2010) 1.07
Current knowledge on pancreatic cancer. Front Oncol (2012) 1.01
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am J Pathol (2009) 0.98
Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res (2013) 0.98
Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer (2002) 0.90
Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation. World J Gastroenterol (2013) 0.90
Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. Cancer Sci (2013) 0.90
Mechanisms of KGF mediated signaling in pancreatic duct cell proliferation and differentiation. PLoS One (2009) 0.89
Fas and Fas-ligand expression in human pancreatic cancer. Ann Surg (2000) 0.88
Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells. Nucleic Acids Res (2001) 0.84
IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene (2013) 0.84
Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth. Cancer Gene Ther (2009) 0.83
Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells. Oxid Med Cell Longev (2012) 0.81
Oncogenic transformation of normal enterocytes by overexpression of cyclin D1. Dig Dis Sci (2003) 0.78
Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing. PLoS One (2014) 0.77
Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. Int J Mol Sci (2017) 0.75
Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells. Oncol Lett (2017) 0.75
Expression of Rab5a correlates with tumor progression in pancreatic carcinoma. Virchows Arch (2017) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
G1 phase progression: cycling on cue. Cell (1994) 11.62
G1 events and regulation of cell proliferation. Science (1989) 9.73
Primary bioassay of human tumor stem cells. Science (1977) 9.69
Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev (1993) 8.03
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev (1993) 7.41
Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol (1994) 7.40
D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol (1994) 7.35
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell (1993) 7.19
Cancer statistics, 1996. CA Cancer J Clin (1996) 6.85
The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell (1989) 6.68
Physical interaction of the retinoblastoma protein with human D cyclins. Cell (1993) 5.31
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene (1995) 3.96
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res (1996) 3.89
Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene (1993) 2.99
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
In vivo association of E2F and DP family proteins. Mol Cell Biol (1995) 1.99
DP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol (1994) 1.94
Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res (1997) 1.92
Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res (1995) 1.89
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer (1994) 1.82
Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol (1996) 1.75
Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene (1995) 1.69
Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst (1996) 1.61
Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A (1987) 1.51
A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A (1994) 1.41
Cyclins and oncogenesis. Biochim Biophys Acta (1993) 1.41
Mammalian G1 cyclins. Curr Opin Cell Biol (1994) 1.39
Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res (1993) 1.36
Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res (1997) 1.33
Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A (1986) 1.33
Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol (1995) 1.17
Protein kinases and cell cycle control. Semin Cell Biol (1994) 1.13
Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene (1997) 1.08
Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene (1995) 1.08
Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology (1996) 1.05
Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int J Cancer (1996) 0.96
Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther (1996) 0.95
Multimodal therapies in ductal pancreatic cancer. The future. Int J Pancreatol (1997) 0.94
Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors (1993) 0.93
Tumor necrosis factor up-regulates gamma-interferon binding in a human carcinoma cell line. J Biol Chem (1990) 0.88
Antisense strategies in neurobiology. Neurochem Int (1997) 0.83
Specific regulation of gene expression by antisense nucleic acids: a summary of methodologies and associated problems. Artif Organs (1996) 0.78
Antineoplastic drugs in 1990. A review (Part II). Drugs (1990) 0.77
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology (1993) 2.86
The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 2.22
Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science (1988) 2.22
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev (1998) 2.04
Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res (1995) 1.89
Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology (1996) 1.85
Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer (1999) 1.81
Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. Am J Physiol (1978) 1.80
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci U S A (2000) 1.67
Appendectomy is more frequent but not a risk factor in Crohn's disease while being protective in ulcerative colitis: a comparison of surgical procedures in inflammatory bowel disease. Am J Gastroenterol (2001) 1.63
The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 1.63
Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci (2003) 1.60
KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res (1996) 1.59
Pancreatic islet-acinar cell interaction: amylase messenger RNA levels ar determined by insulin. Science (1981) 1.59
Halitosis and Helicobacter pylori. A possible link? J Clin Gastroenterol (1992) 1.56
Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res (2001) 1.55
Septic arthritis of the glenohumeral joint. A report of 11 cases and review of the literature. Medicine (Baltimore) (1998) 1.54
Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res (1993) 1.53
Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A (1987) 1.51
Localization of a gene causing cystinuria to chromosome 2p. Nat Genet (1994) 1.48
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res (1990) 1.45
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas (1999) 1.41
A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A (1994) 1.41
Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol (1999) 1.38
Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer (2000) 1.37
Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology (1999) 1.36
Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res (1993) 1.36
Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res (1997) 1.36
Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann Surg (1999) 1.35
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg (1999) 1.34
Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol (1999) 1.33
Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A (1986) 1.33
Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res (1994) 1.32
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer (2000) 1.30
Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol (1998) 1.30
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg (1999) 1.27
A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene (2011) 1.27
Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer (1995) 1.26
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol (2009) 1.26
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res (1998) 1.24
Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res (1994) 1.23
Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer (2001) 1.21
Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res (1995) 1.19
Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun (1994) 1.18
Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med (Berl) (1996) 1.18
Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res (1994) 1.18
Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res (2001) 1.16
Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Clin Cancer Res (1999) 1.15
Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci U S A (1995) 1.13
Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun (1995) 1.13
bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut (1998) 1.12
The streaming adrenal cortex: direct evidence of centripetal migration of adrenocytes by estimation of cell turnover rate. J Endocrinol (1986) 1.12
Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer (2000) 1.12
Synthesis and expression of transforming growth factor beta-1, beta-2, and beta-3 in the endocrine and exocrine pancreas. Diabetes (1993) 1.12
Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem Biophys Res Commun (1996) 1.12
Cytosolic calcium regulates epidermal growth factor endocytosis in rat pancreas and cultured fibroblasts. Proc Natl Acad Sci U S A (1984) 1.10
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol (2011) 1.10
Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. Gastroenterology (1997) 1.09
p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett (1993) 1.09
Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas (1999) 1.08
Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res (2000) 1.08
Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. Clin Cancer Res (1999) 1.08
Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene (1997) 1.08
Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells. Oncogene (2006) 1.08
Differential expression of metastasis-associated genes in papilla of vater and pancreatic cancer correlates with disease stage. J Clin Oncol (2001) 1.07
Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis. Apoptosis (1999) 1.07
Increased expression of acidic and basic fibroblast growth factors in chronic pancreatitis. Am J Pathol (1994) 1.07
Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am J Pathol (1998) 1.07
Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res (1999) 1.07
Increased expression of transforming growth factor beta s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair. Gut (1997) 1.07
Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun (2000) 1.05
Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas (2001) 1.05
Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate (1998) 1.04
Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer (1996) 1.04
The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res (1998) 1.04
Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer (1996) 1.03
Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun (1999) 1.03
Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res (1997) 1.03
Overexpression of platelet-derived growth factor (PDGF) B chain and type beta PDGF receptor in human chronic pancreatitis. Dig Dis Sci (1998) 1.02
Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest (2000) 1.02
Endoscope-induced colitis: description, probable cause by glutaraldehyde, and prevention. Gastrointest Endosc (1995) 1.02
KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. Hepatology (1998) 1.01
Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg (1999) 1.01
Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer (1998) 1.01
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol (2008) 1.01
Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int J Cancer (1997) 1.00
Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology (1998) 1.00
Molecular aspects of pancreatic cancer and future perspectives. Dig Surg (1999) 1.00
Expression of cyclins D1 and E in human colon adenocarcinomas. J Med (1997) 1.00
Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gamma-interferon receptors. Cancer Res (1993) 1.00
The streaming liver. III. Littoral cells accompany the streaming hepatocyte. Liver (1988) 0.99
Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg (1999) 0.99